This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

mepolizumab (Nucala®)

Reference No. 3750

Publication date:

Appraisal information

mepolizumab (Nucala®) 100 mg powder for solution for injection

Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: 06/03/2019
AWMSG meeting date: 10/04/2019
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 0619
Ratification by Welsh Government: 12/04/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

Mepolizumab (Nucala®) is recommended as an option for restricted use within NHS Wales. Mepolizumab (Nucala®) is licensed as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. Mepolizumab (Nucala®) is restricted for use in a subpopulation of the licensed indication in line with the National Institute of Health and Care Excellence recommendation for the restricted use of mepolizumab for treating severe refractory eosinophilic asthma in adults (TA431). Mepolizumab (Nucala®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)